Global Progressive Supranuclear Palsy (PSP) Epidemiology Forecast 2021-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Progressive Supranuclear Palsy (PSP) - Epidemiology Forecast- 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Progressive Supranuclear Palsy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Progressive Supranuclear Palsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epidemiology Perspective:

This section encompassing Progressive Supranuclear Palsy epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Progressive Supranuclear Palsy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.

This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Progressive Supranuclear Palsy epidemiology covered in the report provides historical as well as forecasted Progressive Supranuclear Palsy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Progressive Supranuclear Palsy report covers a detailed overview explaining its etiology, pathophysiology classification, diagnosis, and treatment patterns.
• The Progressive Supranuclear Palsy report and model provide an overview of the global trends of Progressive Supranuclear Palsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Progressive Supranuclear Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Progressive Supranuclear Palsy.
• The report provides the segmentation of the Progressive Supranuclear Palsy epidemiology

Report Highlights

• 11-year Forecast of Progressive Supranuclear Palsy Epidemiology
• 7MM Coverage
• Prevalence of PSP,
• Phenotype associated with PSP
• Gender-specific prevalence of PSP
• Comorbidities associated with PSP

Key Questions Answered:

• What will be the growth opportunities in the 7MM concerning the patient population pertaining to Progressive Supranuclear Palsy?
• What are the key findings pertaining to the Progressive Supranuclear Palsy epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Progressive Supranuclear Palsy across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What are the disease risk, burden, and unmet needs of Progressive Supranuclear Palsy?
• What are the currently available treatments of Progressive Supranuclear Palsy?

Reasons to Buy:

The Progressive Supranuclear Palsy Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Progressive Supranuclear Palsy market.
• Quantify patient populations in the global Progressive Supranuclear Palsy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Progressive Supranuclear Palsy therapeutics in each of the markets covered
• Understand the magnitude of Progressive Supranuclear Palsy population by its epidemiology
• The Progressive Supranuclear Palsy Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments:

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Key Topics Covered:

1 Key Insights

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

4 Progressive Supranuclear Palsy (PSP) Market Overview at a Glance

4.1 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2017

4.2 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Signs and symptoms

5.3 Phenotypes of Progressive Supranuclear Palsy

5.4 History

5.5 Associated risk factors

5.6 Genetics

5.7 Pathophysiology

5.8 PSP associated abnormalities

5.9 Clinical Presentation and Assessment

5.1 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria

5.11 PET Imaging as a Biomarker in Tauopathies

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]

7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)

7.1 The United States

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Patient Population of PSP in the United States

7.1.3 Phenotype associated with PSP in the United States

7.1.4 Gender-specific Prevalence of PSP in the United States

7.1.5 Comorbidities associated with PSP in the United States

7.2 EU5 Countries

7.2.1 Assumptions and Rationale

7.2.2 Germany

7.2.3 France

7.2.4 Italy

7.2.5 Spain

7.2.6 The United Kingdom

7.3 Japan

8 Treatment

8.1 Current symptomatic treatment

9 Unmet Needs

10 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/xpqyog